A Dose-masked Study of Intravitreal Remigromig (EYE103) in Participants With NVAMD or Macular Edema Following BRVO

Inclusion Criteria: Key General Inclusion Criteria • Be willing and able to understand the study procedures and the risks involved and provide written informed consent before the first study-related activity Key Neovascular Age-related Macular Degeneration (NVAMD)-specific Inclusion Criteria * Be ≥ 50 years of age * Have treatment naive subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) or juxtafoveal/extrafoveal CNV with foveal involvement * For participants who are treatment naïve for NVAMD, the diagnosis must have been made within 21 days prior to the Day 1 study treatment Key Incomplete Responder (IR) NVAMD-specific Inclusion Criteria * Be ≥ 50 years of age * Have subfoveal CNV secondary to AMD or juxtafoveal/extrafoveal CNV with foveal involvement at initial screening * For participants who are treatment experienced for NVAMD, the diagnosis must have been made within 90 days prior to the Screening Visit 2 Key Branch Retinal Vein Occlusion (BRVO)-specific Inclusion Criteria * Be diagnosed with BRVO in the study eye * Have a decrease in vision in the study eye determined by the Investigator to be primarily the result of BRVO * Be treatment naïve with vision loss in the study eye and have center-involving macular edema diagnosed within 9 months of Screening Exclusion Criteria: Key General Exclusion Criteria * Pregnant or breastfeeding * History of cataract surgery and/or minimally invasive glaucoma surgery in the study eye within 90 days of Screening * Have had Yttrium-Aluminum Garnet (YAG) laser capsulotomy in the study eye within 90 days of Screening * Currently using drugs with known retinal toxicity (e.g., Hydroxychloroquine, pentosan polysulfate sodium, and amiodarone) Key NVAMD-specific Exclusion Criteria * Have had previous thermal subfoveal laser therapy in the study eye * Have had previous photodynamic therapy with Visudyne in the study eye Key BRVO-specific Exclusion Criteria * Have macular edema in the study eye considered to be secondary to a cause other than BRVO (eg, diabetic macular edema, NVAMD, Irvine-Gass syndrome) * Have active iris or angle neovascularization or neovascular glaucoma in the study eye